Literature DB >> 9498615

Japanese encephalitis virus antigenic variants with characteristic differences in neutralization resistance and mouse virulence.

S C Wu1, W C Lian, L C Hsu, M Y Liau.   

Abstract

Two different plaque variants of Japanese encephalitis virus were selected from a wild-type Taiwanese isolate using Vero cells. One variant was found to exhibit small plaque morphology with retarded virus replication kinetics in Vero cells, and was demonstrated to be resistant to monoclonal antibody (mAb) E3.3 neutralization. The other variant showed large plaque morphology, was sensitive to mAb E3.3 neutralization, and manifested reduced virulence in mice on both intracranial and intraperitoneal inoculations. These two variants propagated in Vero cells retained high levels of infectivity but had relatively low HA titers as compared with the parent strain. The envelope sequences of these two variants showed four amino acid differences at residues E-85 (Glu/Arg), E-306 (Glu/Gly), E-331 (Ser/Arg), and E-387 (Met/Arg). Our results indicated the neutralizing epitope of Japanese encephalitis virus did not overlap with virus virulence determinant.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9498615     DOI: 10.1016/s0168-1702(97)00098-1

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  19 in total

1.  Cloning and sequencing of complete cDNA of Japanese encephalitis virus YL strain in Taiwan.

Authors:  J J Liu; T H Tsai; T J Chang; M L Wong
Journal:  Virus Genes       Date:  2003       Impact factor: 2.332

2.  Histidine at residue 99 and the transmembrane region of the precursor membrane prM protein are important for the prM-E heterodimeric complex formation of Japanese encephalitis virus.

Authors:  Ying-Ju Lin; Suh-Chin Wu
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 3.  Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion.

Authors:  Melanie A Samuel; Michael S Diamond
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Immunogenicity and protective efficacy of the E. coli-expressed domain III of Japanese encephalitis virus envelope protein in mice.

Authors:  Kaushik Bharati; Y P S Malik; Sudhanshu Vrati
Journal:  Med Microbiol Immunol       Date:  2007-03-22       Impact factor: 3.402

5.  DNA-binding property of recombinant capsid protein of Japanese encephalitis virus.

Authors:  Hsi-Nuan Tseng; Chi-Chang Lee; Min-Liang Wong; Shu-O Chen; Jau-Jin Liu
Journal:  Virus Genes       Date:  2007-02-23       Impact factor: 2.332

6.  Expression of recombinant envelope protein of Japanese encephalitis virus YL strain in Escherichia coli possesses hemagglutination activity.

Authors:  S-O Chen; T-H Tsai; T-J Chang; M-L Wong; H-P Su; J-J Liu
Journal:  Virus Genes       Date:  2004-03       Impact factor: 2.332

7.  The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.

Authors:  Bimmi Shrestha; James D Brien; Soila Sukupolvi-Petty; S Kyle Austin; Melissa A Edeling; Taekyung Kim; Katie M O'Brien; Christopher A Nelson; Syd Johnson; Daved H Fremont; Michael S Diamond
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

8.  Characterization of the GXXXG motif in the first transmembrane segment of Japanese encephalitis virus precursor membrane (prM) protein.

Authors:  Ying-Ju Lin; Jia-Guan Peng; Suh-Chin Wu
Journal:  J Biomed Sci       Date:  2010-05-24       Impact factor: 8.410

9.  Genetic determinants of Sindbis virus mosquito infection are associated with a highly conserved alphavirus and flavivirus envelope sequence.

Authors:  Dennis J Pierro; Erik L Powers; Ken E Olson
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

10.  A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites.

Authors:  Cheng-Wen Lin; Suh-Chin Wu
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.